– Voyager’s TRACER TM capsid platform validated by Pfizer option exercise – – Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER – – Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 – –

Reader Interactions

Leave A Reply